Free Trial
NASDAQ:PTIX

Atrinsic (PTIX) Stock Price, News & Analysis

Atrinsic logo
$2.84 +0.03 (+0.89%)
As of 02:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Atrinsic Stock (NASDAQ:PTIX)

Key Stats

Today's Range
$2.72
$2.86
50-Day Range
$2.69
$3.98
52-Week Range
$2.35
$15.54
Volume
23,661 shs
Average Volume
957,220 shs
Market Capitalization
$1.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Atrinsic Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

PTIX MarketRank™: 

Atrinsic scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Atrinsic.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atrinsic is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atrinsic is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Atrinsic has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Atrinsic's valuation and earnings.
  • Percentage of Shares Shorted

    1.32% of the float of Atrinsic has been sold short.
  • Short Interest Ratio / Days to Cover

    Atrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Atrinsic has recently decreased by 81.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Atrinsic does not currently pay a dividend.

  • Dividend Growth

    Atrinsic does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.32% of the float of Atrinsic has been sold short.
  • Short Interest Ratio / Days to Cover

    Atrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Atrinsic has recently decreased by 81.43%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for PTIX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Atrinsic insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.00% of the stock of Atrinsic is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.97% of the stock of Atrinsic is held by institutions.

  • Read more about Atrinsic's insider trading history.
Receive PTIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atrinsic and its competitors with MarketBeat's FREE daily newsletter.

PTIX Stock News Headlines

Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Protagenic Therapeutics swaps warrants for shares
See More Headlines

PTIX Stock Analysis - Frequently Asked Questions

Atrinsic's stock was trading at $6.86 on January 1st, 2025. Since then, PTIX stock has decreased by 58.5% and is now trading at $2.8450.

Atrinsic Inc. (NASDAQ:PTIX) announced its earnings results on Tuesday, May, 13th. The company reported ($2.75) earnings per share for the quarter.

Atrinsic's stock reverse split on the morning of Monday, May 5th 2025.A 1-14 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atrinsic investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), NVIDIA (NVDA), Cytokinetics (CYTK), Heatwurx (PCSA), Acasti Pharma (ACST) and Akero Therapeutics (AKRO).

Company Calendar

Last Earnings
5/13/2025
Today
8/08/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTIX
CIK
1022899
Employees
2
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($13.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.53 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-860.52%
Return on Assets
-354.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.86
Quick Ratio
0.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.96 per share
Price / Book
1.45

Miscellaneous

Outstanding Shares
590,000
Free Float
383,000
Market Cap
$1.68 million
Optionable
Not Optionable
Beta
0.34

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PTIX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners